https://www.selleckchem.com/products/azd4547.html
A combination of focused library and virtual screening, hit expansion, and rational design has resulted in the development of a series of inhibitors of RETV804M kinase, the anticipated drug-resistant mutant of RET kinase. These agents do not inhibit the wild type (wt) isoforms of RET or KDR and therefore offer a potential adjunct to RET inhibitors currently undergoing clinical evaluation. Copyright © 2020 American Chemical Society.Parkinson's disease (PD) is a debilitating and common neurodegenerative disease. New insights implicating c
Like
Comment
Share